Neoplasia Endocrina múltiple, una Revisión y Actualización de tema sobre una Entidad de Diagnóstico y Manejo Complejo
Resumen
Los síndromes de neoplasia endocrina múltiple (NEM) incluyen NEM1, NEM2 (anteriormente NEM2A), NEM3 (anteriormente NEM2B) y el recientemente identificado NEM4. Las presentaciones clínicas son variadas y a menudo se relacionan con la sobreproducción de hormonas específicas. Comprender la genética de cada síndrome ayuda a determinar los plazos de detección. Los tratamientos para cada manifestación dependen de la ubicación, el riesgo de recurrencia o malignidad, el exceso de hormonas y la morbilidad quirúrgica. El manejo multidisciplinario debe incluir genetistas, asesores genéticos, endocrinólogos y cirujanos en patologías endocrinas.
Descargas
Citas
Thakker RV. Multiple endocrineneoplasia type 1 (MEN1) and type4 (MEN4). Mol Cell Endocrinol2014;386:2–15.
Brandi ML, Gagel RF, Angeli A,Bilezikian JP, Beck-Peccoz P, Bordi Cet al. Guidelines for diagnosis andtherapy of MEN type 1 and type 2.J Clin Endocrinol Metab2001;86:5658–71.
Thakker RV, Newey PJ, Walls GV,Bilezikian J, Dralle H, Ebeling PRet al.Clinical practice guidelines for multipleendocrine neoplasia type 1 (MEN1).J Clin Endocrinol Metab2012;97:2990–3011.
Allo M, Thompson NW, Harness JK,Nishiyama RH. Primaryhyperparathyroidism in children,adolescents, and young adults.World JSurg1982;6: 771–6.
Thakker RV. Multiple endocrineneoplasia type 1. In: Jameson JL andDe Groot LJ, eds.Endocrinology: Adultand Pediatric,Vol.II,7thedn.Philadelphia, PA: Elsevier Saunders;2016; 2566–93.
eviQ Cancer Treatments Online CIN.Genetic Testing for Heritable Mutations inthe Multiple Endocrine Neoplasia (MEN)1 Gene.2013 [updated 2018 Oct 18;cited 2019 Jun 12]. Available fromURL: https://www.eviq.org.au/cancer-genetics/genetic-testing-for-heritable-mutations/1428-genetic-testing-for-heritable-mutations-in-th-result-interpretation
Trump D, Farren B, Wooding C,Pang JT, Besser GM, Buchanan KDet al.Clinical studies of multiple endocrineneoplasia type 1 (MEN1).QJM1996;89: 653–69.
Marx S, Spiegel AM, Skarulis MC,Doppman JL, Collins FS, Liotta LA.Multiple endocrine neoplasia type 1:clinical and genetic topics.Ann InternMed1998;129: 484–94.
Thomas-Marques L, Murat A,Delemer B, Penfornis A, Cardot-Bauters C, Baudin Eet al. Prospectiveendoscopic ultrasonographic evaluationof the frequency of nonfunctioningpancreaticoduodenal endocrine tumorsin patients with multiple
endocrineneoplasia type 1.Am J Gastroenterol2006;101: 266–73.
Fendrich V, Langer P, Waldmann J,Bartsch DK, Rothmund M.Management of sporadic and multipleendocrine neoplasia type 1 gastrinomas.Br J Surg2007;94: 1331–41.
Trouillas J, Labat-Moleur F, Sturm N,Kujas M, Heymann MF, Figarella-Branger Det al. Pituitary tumors andhyperplasia in multiple endocrineneoplasia type 1 syndrome (MEN1): acase-control study in a series of77 patients versus 2509 non-MEN1patients.Am J Surg Pathol2008;32:534–43.
Beckers A, Betea D, Valdes Socin H,Stevenaert A. The treatment of sporadicversus MEN1-related pituitaryadenomas.J Intern Med2003;253:599–605.
Goudet P, Murat A, Binquet C, Cardot-Bauters C, Costa A, Ruszniewski Pet al.Risk factors and causes of death inMEN1 disease. A GTE (Groupe d’Etudedes Tumeurs Endocrines) cohort studyamong 758 patients.World J Surg2010;34: 249–55.
Wells SA Jr, Asa SL, Dralle H, Elisei R,Evans DB, Gagel RFet al. RevisedAmerican Thyroid Associationguidelines for the management ofmedullary thyroid carcinoma.Thyroid2015;25: 567–610.
Germain A, Klein M, Brunaud L.Surgical management of adrenaltumors.J Visc Surg2011;148: e250–61.
Romei C, Pardi E, Cetani F, Elisei R.Genetic and clinical features of multipleendocrine neoplasia types 1 and 2.J Oncol2012;2012: 705036.
Tacon LJ, Learoyd DL, Robinson BG.Multiple endocrine neoplasia type 2. In:Jameson JL and De Groot LJ, eds.Endocrinology: Adult and Pediatric, Vol.II,7th edn. Philadelphia, PA: ElsevierSaunders; 2016; 2594–605.
Wells SA Jr, Pacini F, Robinson BG,Santoro M. Multiple endocrineneoplasia type 2 and familial medullarythyroid carcinoma: an update.J ClinEndocrinol Metab2013;98: 3149–64.
Znaczko A, Donnelly DE, Morrison PJ.Epidemiology, clinical features, andgenetics of multiple endocrine neoplasia type 2B in a complete population.Oncologist2014;19: 1284–6.
eviQ Cancer Treatments Online CIN.Genetic Testing for Heritable Mutations inthe RET Gene Associated with MultipleEndocrine Neoplasia (MEN) Type 2. 2013[updated 2016 Jun 23; cited 2019 Jun12]. Available from URL: https://www.eviq.org.au/cancer-genetics/genetic-testing-for-heritable-mutations/1429-genetic-testing-for-heritable-mutations-in-th-testing-not-indicated
Gild ML, Naik N, Hoang J, Hsiao E,McGrath RT, Sywak Met al. Role ofDOTATATE-PET/CT in preoperativeassessment of phaeochromocytoma andparagangliomas.Clin Endocrinol (Oxf)2018;89: 139–47.
Wells SA Jr, Robinson BG, Gagel RF,Dralle H, Fagin JA, Santoro Met al.Vandetanib in patients with locallyadvanced or metastatic medullarythyroid cancer: a randomized, double-blind phase III trial.J Clin Oncol2012;30: 134–41.
Elisei R, Schlumberger MJ, Muller SP,Schoffski P, Brose MS, Shah MHet al.Cabozantinib in progressive medullarythyroid cancer.J Clin Oncol2013;31:3639–46.
Pellegata NS, Quintanilla-Martinez L,Siggelkow H, Samson E, Bink K,Hofler Het al. Germ-line mutations inp27Kip1 cause a multiple endocrineneoplasia syndrome in rats andhumans.Proc Natl Acad Sci U S A2006;103: 15558–63.
Alrezk R, Hannah-Shmouni F,Stratakis CA. MEN4 and CDKN1Bmutations: the latest of the MENsyndromes.Endocr Relat Cancer2017;24: T195–208.Multiple endocrine neoplasiaInternal Medicine Journal49(2019) 954–961© 2019 Royal Australasian College of Physicians961
Derechos de autor 2024 María Alejandra Velásquez Quiroga, Cristian Camilo Ballesteros López, Maira Alejandra Puerta Medina, Jonatan Ferley Vasquez Castro, José Miguel Barón Martínez, Natalia Sofía Robles Cuello , Juan Sebastian Sierra Cedeño , Vanya Esther Vargas , Laritza Johana Pérez Ardila
Esta obra está bajo licencia internacional Creative Commons Reconocimiento 4.0.
.png)
.png)
1.png)
